Suspension composition for hematology analysis control

ABSTRACT

A suspension composition for a hematology analysis control particularly useful for preserving relevant detectable characteristics of blood cells for a prolong stability period. The suspension may include at least one polysaccharide, which may include or derive from chitosan and/or chitin, as a stabilizing agent.

TECHNICAL FIELD

The teachings relates generally to hematology analysis and more particularly to suspension compositions for use in a synthetic control (and resulting control compositions), and a synthetic control, for a semi-automated or automated digital imaging hematology analyzers.

BACKGROUND

For decades, the traditional semi-automated or automated approach to hematology analysis has involved flow based techniques. Blood samples have been aspirated into a hematology analyzer and passed through a detection cell. Relevant characteristics of the blood cells have been measured by light scatter characteristics, electrical characteristics, or otherwise. Based upon detected attributes of the cell, the cell will be classified according to its size and the presence of granular nuclear material. In this manner blood cell differentials can be determined for sub-populations of white blood cells.

In accordance with clinical laboratory standards, performance quality and consistent operation of hematology instruments has employed the use of controls typically have been made from blood cell sources that are treated to preserve the relevant detectable characteristics of the cells. Control manufacturers would use either human or animal blood cells as a blood cell source and process them to achieve and retain a size, density and/or morphology representative of a typical subpopulation of cells, as detected by an instrument detection technique. The respective simulated subpopulations could then be combined in a single control composition, optionally with non-leukocyte blood cell components, such as platelets, reticulated platelets, red blood cells, nucleated red blood cells, reticulocytes, immature reticulocytes, or otherwise.

Examples of teachings addressing approaches to making simulated blood components are described, without limitation, in U.S. Pat. Nos. 4,160,644 and 4,436,821 (teaching simulated platelets); U.S. Pat. No. 6,221,668 (teaching simulated reticulocytes, reticulated platelets and nucleated red blood cells); U.S. Pat. No. 5,432,089 (teaching simulated reticulocytes, and that such simulated reticulocytes may be derived from an anemic animal source); U.S. Pat. No. 6,723,563 (teaching simulated nucleated red blood cells); US Published Application No. 20120308985 (teaching simulated immature reticulocytes); The resulting processed cells after transformation from their natural state, would be suspended in a suspension composition adapted to help preserve the processed cells and enable proper function within an instrument. It was a common practice to suspend the cells in a medium that included lipoprotein. This is described, for example, in U.S. Pat. Nos. 5,270,208 and 5,262,327.

Examples of patents describing the processing of cells from a non-human cell source to form white blood cell subpopulation analogs include U.S. Pat. No. 5,512,485; see also, U.S. Pat. No. 4,704,364. Other examples of teachings of making simulated blood components include United States Patent Application 20030104631; U.S. Pat. Nos. 6,653,063; 6,514,763; and 5,858,790.

In recent years, efforts have been devoted toward development of semi-automated or automated hematology analyzers that employ digital imaging to analyze patient blood. Assuring instrument integrity and consistency of results remains a challenge for instrument producers and operators. As with traditional semi-automated or automated hematology instruments, the digital imaging instruments require regular quality control testing using one or more convenient and accessible control compositions that yield consistent and reproducible results for a prolonged period of time, and well beyond the useful life of fresh whole blood (e.g., fresh human whole blood).

Due to different detection techniques employed as between traditional semi-automated or automated hematology analyzers and digital imaging hematology analyzers, conventional hematology controls are not necessarily useful with digital imaging hematology analyzers. There is thus a need for new compositions for use in a control for semi-automated or automated digital imaging hematology analyzers. There is a need for a new composition that that provides relatively long term stability of simulated white blood cells (e.g., at least about 3 days, 7 days, 14 days, 30 days, 45 days, 90 days or longer, such as at least about 105 days) when stored at about 2 to about 10° C. There is a need also for a new composition that allows simulated blood cells to be dispensed (e.g., printed) onto a substrate for delivering the simulated blood cells for semi-automated or automated analysis by digital imaging while on the substrate.

SUMMARY

In general, the present teachings address one or more of the above needs by providing a synthetic control composition for a semi-automated or automated digital imaging hematology analyzers. The present teachings address one or more of the above needs by providing a unique suspension composition into which simulated blood cells (e.g., cells that include simulated nucleated blood cells) can be dispersed to form a synthetic control composition for a semi-automated or automated hematology analyzer, and particularly a digital imaging hematology analyzer. In this regard, the present teachings also relate generally to synthetic compositions for assuring quality control of a digital imaging hematology analyzer. The compositions generally will include one or more simulated blood components (which may be derived from one or more processed blood cells) and a suspension composition in accordance with the present teachings. The suspension component is such that stability of the one or more simulated blood components is prolonged significantly as compared with fresh whole blood (e.g., fresh human whole blood).

The teachings herein relate as well to a synthetic control composition that includes, in a unique suspension composition, one or any combination of components for simulating a platelet, a reticulated platelet, a red blood cell, reticulocyte, an immature reticulocyte, a nucleated red blood cell, or a simulated leukocyte population or sub-population and is useful as a quality control composition for a digital imaging hematology analyzer. The synthetic control of the teachings may be useful as a quality control composition for a digital imaging hematology analyzer for analyzing a three-part leukocyte differential, a five-part leukocyte differential, and/or an expanded differential leukocyte analysis (also referred to as an expanded differential white blood cell (“dWBC”) analysis).

It can be seen that the synthetic control composition of the teachings may include simulated leukocytes (which may be derived from a human or other source, as discussed herein) provided as an individual subpopulation of leukocytes, and/or a collection of cells capable of differentiation into at least the three and/or the five traditional subpopulations of leukocytes, and/or the simulated leukocytes may be suitable for providing an expanded differential white blood cell (“dWBC”) analysis and for total white blood cell count or cell count for any white blood cell sub population.

With attention now to certain other generalities about the present teachings, it can be said that the teachings herein relate generally to a composition adapted for use in assuring quality control of a digital imaging hematology analyzer, including a suspension medium with which at least one simulated nucleated blood component is mixed in a predetermined amount, the suspension medium including a stabilizing agent capable of preserving relevant detectable size and morphology, including detectable nuclear morphological characteristics of the nucleated blood component (including any native nuclear cytoplasm granules), when stored at about 2 to about 10° C. for a period of at least 3 days, 7 days, 14 days, 30 days, 45 days, 90 days or longer, such as at least about 105 days) from the time when the at least one simulated nucleated blood component is initially mixed with the suspension medium.

The control composition in which the suspension composition of the teachings is useful may be a synthetic control composition for simulating one or more components of blood (e.g., human whole blood). The control composition in which the suspension composition of the teachings is useful may be a control composition for simulating cells of a leukocyte population of whole blood (e.g., simulated nucleated blood cells to resemble a leukocyte population or one or more subpopulations). Examples of a leukocyte population of whole blood for use in a control composition with the present suspension composition include a three-part leukocyte population of whole blood (e.g., the control may be to simulate three leukocyte subpopulations of whole blood (namely, neutrophils, lymphocytes and monocytes)), a five-part leukocyte population of whole blood (e.g., the control may be to simulate the traditional five leukocyte subpopulations of whole blood (namely, neutrophils, eosinophils, basophils, lymphocytes, and monocytes)), and/or an extended leukocyte population of whole blood (e.g., the control may include further subpopulations of one or more of the traditional five leukocyte subpopulations of whole blood). An example of another simulated nucleated cell component is a nucleated red blood cell. The suspension composition of the present teachings are also useful to preserve simulated reticulocytes, an immature reticulocyte fraction, or both.

The suspension composition may be employed in a synthetic control composition. The suspension composition may be employed in a synthetic control composition in combination with simulated blood cells (e.g., simulated nucleated blood cells, such as a simulated leukocyte population or sub-population of whole blood and/or a simulated nucleated red blood cell). A simulated leukocyte population or subpopulation of whole blood, for the present teachings, may be derived at least partially, or entirely from leukocytes of human whole blood. The simulated leukocyte population or subpopulation of whole blood may include cells that have been treated in a manner to stabilize their respective cell membranes so that the cells remain substantially intact for a period of time that is longer than cells that are not stabilized. It is possible that all simulated leukocytes of a leukocyte population, including the respective subpopulations, are treated simultaneously (e.g., according to a sequence of one or more partial or complete fixing and lysing steps) to provide the simulated leukocytes.

The suspension composition may be employed in a control composition, in combination with one or more components for simulating a platelet, a reticulated platelet, a red blood cell, reticulocyte, an immature reticulocyte, a nucleated red blood cell, or any combination thereof. For example, the suspension composition may be employed in a control composition in combination with a simulated nucleated red blood cell prepared from a non-human source (e.g., nucleated blood cells of a bird such as a turkey, a fish, or a reptile such as an alligator). For example, it may be possible to provide a source of blood cells suitable for simulating a nucleated red blood cell. Provided blood cells may individually include a membrane enclosing a nucleus and cytoplasm. The membrane may be stabilized to retain the nucleus and cytoplasm. For example, there may be a step of lysing the cells that are provided (e.g., with a solution including saponin) and then fixing with an aldehyde (e.g., glutaraldehyde and/or formaldehyde). It is also possible that no lysing step would be utilized prior to cell fixation.

The amounts of simulated cells in the suspension composition generally are predetermined; for example, the amounts may be known amounts for simulating normal amounts in whole blood and/or abnormal amounts). The suspension composition may be useful in a stand-alone control composition, in which typically a single simulated blood cell component is employed.

In contrast with prior control compositions, the control composition of the present teachings need not necessarily employ a lipoprotein to help assure proper characterization and differentiation of simulated leukocyte cells into their proper subpopulations. The present teachings make use of the recognition that certain stabilization agents can be mixed in a suspension composition with a volume of simulated white blood cells, and for a prolonged period (e.g., at least about 3 days, 7 days, 14 days, 30 days, 45 days, 90 days or longer, such as at least about 105 days, when stored at about 2 to about 10° C.) from the time of mixing, simulated cell components (including the simulated leukocytes) retain relevant detectable size and morphology, including detectable nuclear morphological characteristics of the cell and its nuclear matter, including native nuclear cytoplasm granules. However, it is also possible that lipoprotein may be utilized.

According to one general aspect of the teachings applicable to all embodiments, there is contemplated a suspension composition for simulated leukocytes (e.g., cells that have similar detectable characteristics, such as size, a nucleus morphology and/or morphology of other native nuclear cytoplasm granules, of one or any combination of sub-populations of whole blood) of a hematology analyzer control formulation. The suspension composition is especially useful for a control for a semi-automated or automated digital imaging analyzer. The suspension composition is adapted to retain the detectable characteristics of the simulated blood cells (e.g., simulated nucleated cells such as nucleated leukocytes and/or nucleated red blood cells) over a prolonged period of storage. The suspension composition may include a buffered aqueous solution.

As to all embodiments, the suspension composition may include at least one stabilizing agent (e.g., one that includes at least one polysaccharide, such as (without limitation) a nitrogen-containing polysaccharide) having a polymerization degree ranging from greater than one to about 100). The at least one stabilizing agent may be present in an amount sufficient for preserving stability of the detectable size and morphological characteristics of the simulated simulated blood cells (e.g., simulated nucleated cells such as nucleated leukocytes and/or nucleated red blood cells) for a period of at least about 3 days (e.g., at least about 3 days, 7 days, 14 days, 30 days, 45 days, 90 days or longer, such as at least about 105 days) when stored at about 2 to about 10° C.), from the time of suspending the simulated cells.

Generally, the suspension composition may be adapted (as to all embodiments) for use in digital imaging hematology instrument that creates and analyzes an image, such as by applying one or more automated or semi-automated analytical techniques, after a sample has been dispensed onto a substrate. For instance, upon mixing the suspension composition with the simulated leukocytes, the resulting mixture is capable of dispensing through a nozzle for delivery to a substrate for analysis by a digital imaging hematology analyzer. The suspension composition may be adapted, upon mixing with the simulated blood cells (e.g., simulated nucleated cells such as nucleated leukocytes and/or nucleated red blood cells), for dispensing through a nozzle (e.g., a capillary or other tube) for delivery by printing to a transparent substrate (e.g., a glass or polymeric slide) and subsequent analysis by a semi-automated or automated digital imaging hematology analyzer, without any material damage (e.g., damage to excess of five percent (10%) by number of total simulated cells) to the simulated cells. It is possible that the control composition may be delivered into a cassette or cartridge device which may provide digital images for identifying cell populations.

In general, as to all embodiments, the aqueous buffered solution of the suspension composition may include at least one buffering agent.

The aqueous buffered solution may include at least one dispersion agent for reducing aggregation of the simulated blood cells (e.g., simulated nucleated cells such as nucleated leukocytes and/or nucleated red blood cells) as compared with the aqueous buffered solution without the dispersion agent.

The suspension composition may have a pH ranging from about 6 to about 8.

The at least one stabilizing agent may include an organic compound having at least one glycosidic linkage. The at least one stabilizing agent may include a compound that includes an amine moiety and a carbohydrate (e.g., glucose and/or dextrose) moiety.

The at least one stabilizing agent may include at least one amino polysaccharide having a polymerization degree ranging from greater than one to about 100 (e.g., from greater than about 5 to about 40). The at least one stabilizing agent may include or consist of an oligosaccharide (or a derivative of an oligosaccharide) having a weight average molecular weight (measured by high performance liquid chromatography, which may be further verified by comparison with commercially available standards)) from about 100 to about 15,000 daltons (Da), from about 250 to about 10,000 Da, about or even about 1000 to about 3000 Da.

The at least one stabilizing agent may include a glucosamine, or a derivative thereof. It may include one or more of a chitosan and/or chitin, a salt of a chitosan and/or chitin, and/or some other derivative of a chitosan and/or chitin.

The at least one stabilizing agent may be in a polymeric form. The at least one stabilizing agent may be in a salt form (e.g., a salt of a chitosan and/or chitin). Illustrative salts include one or any combination of a citrate, a malate, a lactate, an acetate, a formate, a glyoxylate, a pyruvate, an ascorbate or glycolate.

Generally applicable to all embodiments, the at least one stabilizing agent may be present in an amount up to about ten percent (15%) (e.g., up to about ten percent (10%) or about seven percent (7%)) of the suspension composition. The at least one stabilizing agent may be present in an amount up to about ten percent (10%) (e.g., up to about seven percent (7%) or about five percent (5%) of a resulting control composition admixture including the suspension composition and the simulated cells.

Unlike certain control compositions of the prior art, the suspension composition and any resulting control composition employing the suspension composition of the general teachings herein may be substantially free of any added lipid (e.g., lipoprotein), any glycoprotein or both.

The teachings herein also contemplate a blood control composition (e.g., leukocyte and/or nucleated red blood cell-containing control) composition adapted for use in a semi-automated or automated digital imaging hematology analyzer comprising the suspension composition of the teachings, as well as the use of the composition. For instance, the teachings envision a method of using the suspension composition including a step of dispensing the suspension composition onto a substrate, and at least partially evaporating water from the aqueous buffered suspension composition. Thereafter, a digital image can be made. For instance, when cells are deposited onto a substrate with the suspension composition, a digital image may be made of the cells. The image may be analyzed. For instance the image may be analyzed by a computer implemented technique.

Other benefits and advantages of the teachings will be understood upon review of the remaining teachings, which provide additional details.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a micrograph illustrating cells of fresh human whole blood, as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be detectable by a digital imaging hematology analyzer.

FIG. 2 is a micrograph illustrating simulated leukocytes cells in a freshly prepared suspension composition of the present teachings as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be analyzed by a digital imaging hematology analyzer.

FIG. 3a is an enlarged micrograph illustrating respective examples of simulate leukocyte subpopulation cells and other simulated cell components in a suspension composition of the present teachings as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be analyzed by a digital imaging hematology analyzer.

FIG. 3b is an enlarged micrograph illustrating respective examples of leukocyte subpopulation cells and other simulated cell components after storage at about 2 to about 10° C. for 105 days in a suspension composition of the present teachings as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be analyzed by a digital imaging hematology analyzer.

FIG. 4a is a micrograph to illustrate an example of simulated leukocyte cells in a suspension medium including a stabilizing agent of the present teachings after about three weeks as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be analyzed by a digital imaging hematology analyzer.

FIG. 4b is a micrograph to illustrate an example of simulated leukocyte cells of the present teachings in a suspension medium as in FIG. 4a , but absent any stabilizing agent of FIG. 4a after about three weeks as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be analyzed by a digital imaging hematology analyzer.

FIG. 5 is a micrograph to illustrate an example of a prior art hematology control, absent any stabilizing agent of the present teachings, as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be analyzed by a digital imaging hematology analyzer.

DETAILED DESCRIPTION

The explanations and illustrations presented herein are intended to acquaint others skilled in the art with the teachings, its principles, and its practical application. Those skilled in the art may adapt and apply the teachings in its numerous forms, as may be best suited to the requirements of a particular use. Accordingly, the specific embodiments of the present teachings as set forth are not intended as being exhaustive or limiting of the teachings. The scope of the teachings should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. The disclosures of all articles and references, including patent applications and publications, are incorporated by reference for all purposes. Other combinations are also possible as will be gleaned from the following claims, which are also hereby incorporated by reference into this written description.

This application claims the benefit of the filing date of U.S. Provisional Application Ser. No. 62/368,676, filed Jul. 29, 2016 and 62/454,224, filed Feb. 3, 2017, the contents of these applications being hereby incorporated by reference herein for all purposes.

Unless otherwise stated, concentrations are expressed in weight/volume percentages (w/v %). Thus, to illustrate, 1% of an ingredient in a liquid medium would refer to 1 gram of the ingredient in 100 milliliters of the liquid. Unless otherwise stated, references herein to “whole blood” and/or “blood cells”, include human whole blood. Though the teachings herein are particularly applicable in human whole blood analysis, they are not so limited, and may have application in veterinary applications as well. The phrase “digital imaging hematology instrument” refers to automated hematology analyzers of an automated or semi-automated type that employ computer implemented analysis of a digital image of a sample (e.g., a computer may analyze the sample to ascertain cell size, cell morphology, count cells, and/or classify cells, and may also output resulting data and/or images for independent human analysis). An example of such analysis technology is exemplified by the Cobas m511™, by Roche Diagnostics, which employs what is referred to as Bloodhound™ analysis technology. It is believed that such technology is described in one or more of U.S. Patent Application Nos. 20090269799; 20110014645; 20130070077; 20130077085; and WO/2013/016038.

The phrase “detectable characteristics” refers to one or more characteristics (e.g., a physical characteristic, such as size and/or morphology) that are detectable by a hematology instrument, whether a digital imaging hematology instrument or otherwise.

In general, the teachings herein contemplates a suspension composition for preserving the stability of simulated blood cells of a hematology control composition. The teachings more particularly contemplates a suspension composition for preserving the stability of simulated blood cells, so that the cells exhibit and retain relevant detectable characteristics, such as size, and/or morphology. One particular advantage of the teachings is the ability of the suspension composition to preserve the stability nuclear morphological characteristics (including morphology of native nuclear cytoplasm granules) for a period substantially longer than fresh human whole blood. The suspension composition teachings are useful to prepare a suspension of a control composition for assuring quality of a hematology analyzer (e.g., a digital imaging hematology analyzer).

In general, the suspension composition is useful for and may be part of a control composition that include the suspension and simulated blood cells (e.g., simulated nucleated cells such as nucleated leukocytes and/or nucleated red blood cells). Such control composition and methods of using the controls are part of the teachings herein as well.

Determination of whether relevant detectable characteristics are retained can be done by optical examination (e.g., including the use of a digital imaging device for outputting an image) of a statistically significant number of samples, with analysis to identify material deviations from native morphological attributes of the type of cell under consideration. Indicators of material deviations can employ optical means to identify. It may include a comparative study of a sample with data (which may include images) about known characteristics of the sample material in its normal freshly prepared state. The skilled person likewise would recognize that relevant detectable characteristics have not been attained, or are no longer retained (e.g., a stability period has been exceeded) when a sample intended yields cell counts that deviate from the intended values in excess of at least ten percent (10%), or there is some other evidence indicative of an inability to differentiate cells; when nucleated blood cells present identifiable surface cracks in images at a magnification of at least 100× (e.g., when viewed by optical microscopy with an oil immersion lens); when cellular cytoplasm appears de-granulated and not readily identifiable in images at a magnification of at least 100× (e.g., when viewed by optical microscopy with an oil immersion lens), and/or when one or more nuclei sizes deviate from their normal well known sizes.

It should thus be recognized, that the phrase “simulated blood cells” is used herein not only to refers to cells from a non-human source that are adapted to resemble blood cells from a human (or those of another species) in relevant detectable characteristics by a hematology analyzer (e.g., a digital imaging analyzer). The phrase “simulated blood cells” also refers to blood cells that are true human blood cells. Thus, a source of simulated white blood cells, in accordance with the teachings herein may be human white blood cells. Moreover, any of the simulated blood cells that are suspended in the suspension composition may be cells derived from human whole blood and/or non-human whole blood source (e.g., blood from a source selected from avian blood, fish blood, reptilian blood, mammalian blood or otherwise.

The suspension composition may be employed in a control composition, alone or in combination with simulated blood cells, which may include simulated leukocytes or other simulated cell components of whole blood (e.g., simulated nucleated cells such as nucleated leukocytes and/or nucleated red blood cells). A simulated leukocyte population or subpopulation of whole blood may be derived at least partially, or entirely from leukocytes of human whole blood. The simulated leukocyte population or subpopulation of whole blood may include cells that have been treated in a manner to stabilize their respective cell membranes so that the cells remain substantially intact for a period of time that is longer than cells that are unstabilized. It is possible that all simulated leukocytes of a leukocyte population, including the respective subpopulations, are treated simultaneously to provide the simulated leukocytes. For example, a source of leukocytes (e.g., a leukocyte pack from a blood bank) may be provided and the leukocytes contacted with a stabilizer to partially stabilize the cell membranes of the leukocytes. The source is then lysed to eliminate red blood cells. The leukocytes may then be further stabilized prior to combining them with the suspension.

In general, the present teachings provide a unique suspension composition into which simulated blood cells can be dispersed to form a control composition. In contrast with prior control compositions, the control composition of the present teachings need not necessarily employ a lipoprotein to help assure proper characterization of simulated leukocytes and/or differentiation of the simulated blood cells into their proper subpopulations.

The present teachings make use of the recognition that certain stabilization agents can be mixed in a suspension composition with a volume of simulated blood cells (e.g., for simulation one or more subpopulations of white blood cells), and for a prolonged stability period (e.g., at least about 3, at least about 7, at least about 14, at least about 30, at least about 45, at least about 90 days or longer, e.g., at least about 105 days, while maintained at a temperature of about 2 to about 10° C.) from time of mixing, the simulated blood cells (e.g., simulated leukocytes, and any other simulated blood cell component such as a nucleated red blood cell component) retain relevant detectable characteristics such as size and/or nuclear morphological characteristics (including morphology of native nuclear cytoplasm granules).

According to one general aspect of the teachings applicable to all embodiments, there is contemplated a suspension composition for simulated blood cells of a hematology analyzer control formulation, which may be a digital imaging hematology analyzer. The simulated blood cells may be cells from a suitable source that have been processed to attain and/or preserve characteristics detectable by a hematology analyzer, such as a digital imaging hematology analyzer. For instance, the characteristics that are attained and/or preserved may be size, a nucleus morphology and/or morphology of other nuclear cytoplasm granules.

The teachings herein have application for suspending and preserving stability of simulated blood components (e.g., blood cells) in a control composition. For example, the teachings have application for suspending and preserving stability of simulated leukocytes of a control composition. The simulated leukocytes (which may be derived from a human or other source, as discussed above) may be provided as an individual subpopulation of leukocytes, and/or a collection of cells capable of differentiation into at least the three and/or the five traditional subpopulations of leukocytes. The simulated leukocytes may be suitable for providing an expanded differential white blood cell (“dWBC”) analysis.

A control in accordance with the teachings for an expanded dWBC analysis may include (e.g., in addition to the traditional 3 or 5 subpopulations) components that simulate one or more cell populations that may include blasts, immature granulocytes, atypical lymphocytes (types I, II and III), myeloid precursors (myeloblast, promyelocyte, myelocyte and metamyelocyte) and or lymphocyte subsets (T-Cells and B-Cells).

The suspension composition is adapted to retain the detectable characteristics of the simulated blood cells (e.g., white blood cells) over a prolonged period of storage. For example, the suspension composition (whether used for simulated white blood cells and/or other blood cells is formulated to preserve relevant detectable characteristics, such as size and/or nuclear morphological characteristics (including morphology of native nuclear cytoplasm granules) of the simulated blood cells, for a prolonged stability period (e.g., at least about 3, at least about 7, at least about 14, at least about 30, at least about 45, at least about 90 days or longer, e.g., at least about 105 days) when stored at about 2 to about 10° C. from time of mixing with the suspension composition.

Throughout the prolonged stability period, the nucleated cells (e.g., the simulated leukocytes (and/or any other simulated cell components such as simulated nucleated red blood cells) will resemble to a detector of a hematology analyzer, and particularly a digital imaging hematology analyzer (e.g., without limitation, a COBAS m511™ analyzer from Roche) the blood cell it is intended to simulate. Thus, the simulated blood cell is capable of being subjected to sample processing by a digital imaging hematology instrument, during which the cell may be deposited on a slide (such as by a printing operation), stained, and imaged in a manner suitable for computer implemented image analysis.

The suspension composition may be isotonic. The suspension composition may include a buffered aqueous solution. The suspension composition may include a mixture of cell stabilizers. The suspension composition may include an antimicrobial. The suspension composition may include one or more agents for maintaining a predetermined pH.

As to all embodiments, the suspension composition may include at least one stabilizing agent (e.g., one that includes at least one polysaccharide having a polymerization degree ranging from greater than one to about 100, such as (without limitation) a nitrogen containing polysaccharide). The at least one stabilizing agent may be present in an amount sufficient for preserving stability of the detectable morphological characteristics of the white blood cells for a period of at least about 3 days (e.g., at least about 7, at least about 14, at least about 30, at least about 45, at least about 90 days or longer, e.g., at least about 105 days), after being stored during such period at about 2 to about 10° C., upon suspending the simulated white blood cells.

Generally, the suspension composition may be adapted (as to all embodiments) for use in digital imaging hematology instrument that creates and analyzes by a computer implemented technique an image of a sample that has been dispensed onto a substrate. For instance, upon mixing the suspension composition with the simulated leukocytes, the resulting mixture is capable of dispensing through a nozzle for delivery to a substrate for analysis by a digital imaging hematology analyzer. The suspension composition may be adapted, upon mixing with the simulated white blood cells, for dispensing through a nozzle (e.g., a capillary or other tube) for delivery by printing to a transparent substrate (e.g., a glass or polymeric slide) and subsequent analysis by a digital imaging hematology analyzer, without any material damage (e.g., damage to excess of five percent (10%) by number of total simulated blood cells) to the simulated blood cells.

The at least one stabilizing agent may be present (as to all embodiments) in an amount sufficient for preserving stability of the detectable morphological characteristics of the white blood cells for a period of at least 30 days, after being stored during such period at about 2 to about 10° C., upon suspending the white blood cells. More specifically, as applicable to the teachings in general, the at least one stabilizing agent may function to retain intact relevant detectable characteristics such as size and/or nuclear morphological characteristics (including morphology of native nuclear cytoplasm granules) of one or more of any simulated nucleated blood cell component of a control composition. Thus, the size and shape of a nucleus of the simulated blood cell be preserved substantially as it would be in its native state in fresh whole blood. It is also possible that the size, shape and/or amount of other nuclear matter (e.g., cytoplasm) may be preserved substantially as it would be in its native state in fresh whole blood.

The at least one stabilizing agent may be part of a stabilization mixture. Such stabilization mixture may include two, three, four, five or more ingredients. Such stabilization mixture may include twelve, ten, eight or fewer ingredients. The ingredients of the stabilization mixture may be in an amount effective for stabilizing one or more aspects of a simulated blood cell (e.g., a simulated leukocyte or any other simulated blood cell component, such as a platelet, a reticulated platelet, a red blood cell, reticulocyte, an immature reticulocyte, a nucleated red blood cell, or any combination thereof). For example, one or more of the ingredients may be for stabilizing a membrane, for stabilizing nuclear material, for stabilizing a nucleic acid, for stabilizing cytoplasm, or otherwise).

In general, as to all embodiments, the aqueous buffered solution of the suspension composition may include at least one buffering agent. It may include at least one antimicrobial. The aqueous buffered solution may include at least one dispersion agent for reducing aggregation of the simulated white blood cells as compared with the aqueous buffered solution without the dispersion agent. The suspension composition may have a pH ranging from about 6 to about 8.

In general, as to all embodiments, with regard to the at least one stabilizing agent, it may include at least one polysaccharide, such as is set forth in the following. The at least one stabilizing agent may be a nitrogen-containing polysaccharide. The at least one stabilizing agent may be a derivative of glucose. It may include one or more glucose moieties. However, the at least one stabilizing agent may be substantially free of simple glucose (i.e., that represented by the formula C₆H₁₂O₆); that is, the suspension medium may include less than about 10%, or less than about 5% glucose of the suspension medium.

For example, the at least one stabilizing agent may include at least one amino polysaccharide having a polymerization degree ranging from greater than one to about 100 (e.g., from greater than about 5 to about 40). The at least one stabilizing agent may include or consist of an oligosaccharide (or a derivative of an oligosaccharide) having a weight average molecular weight (measured by high performance liquid chromatography, which may be further verified by comparison with commercially available standards)) from about 250 to about 10,000 daltons (Da), from about 250 to about 10,000 Da, or even about 1000 to about 3000 Da.

The at least one stabilizing agent may include a glucosamine, or a derivative thereof. It may include one or more of a chitosan, a salt of a chitosan or some other derivative of a chitosan.

The at least one stabilizing agent may be in a polymeric form. The at least one stabilizing agent may be in a salt form (e.g., a salt of a chitosan). Illustrative salts include one or any combination of a citrate, a malate, a lactate, an acetate, a formate, a glyoxylate, a pyruvate, an ascorbate or glycolate.

By way of example, the at least one stabilizing agent may include one or any combination of D-(+)-glucosamine, N-acetyl-D-glucosamine, chitosan acetate, chitosan lactate, chitosan oligosaccharide, chitin, carboxyl methyl chitosan, a derivative of any of these listed agents, or any combination of the same.

Generally applicable to all embodiments, the at least one stabilizing agent may be present in an amount up to about fifteen percent (15%) (e.g., up to about ten percent (10%) or about seven percent (7%)) about ten percent (10%) or about seven percent (7%)) of the suspension composition. The at least one stabilizing agent may be present in an amount up to about ten percent (10%) (e.g., up to about seven percent (7%) or about five percent (5%) of a resulting control composition admixture including the suspension composition and the white blood cells. Generally applicable to all embodiments, the at least one stabilizing agent along with any other ingredients functional for preserving stability of a simulated blood cell (i.e., the total functional ingredients of the stabilizing mixture), may be present in amount up to about twenty five percent (25%); twenty two percent (22%); or about eighteen (18%) (e.g., up to about fifteen percent (15%) or about ten percent (10%)) of the suspension composition. The total functional ingredients of the stabilizing mixture may be present in an amount of at least about one percent (1%) (e.g., at least about seven percent (3%) or about five percent (5%)) of a resulting control composition admixture including the suspension composition and the white blood cells.

Unlike certain control compositions of the prior art, the suspension composition and any resulting control composition employing the suspension composition of the general teachings herein may be substantially free of any added lipid (e.g., lipoprotein), any glycoprotein or both. For example, it may have less than 0.3 percent (e.g., less than about 0.1 percent) of a lipid and/or glycoprotein. Alternatively stated, to the extent any lipid (e.g., lipoprotein), any glycoprotein or both are employed in a suspension composition in accordance with the present teachings, such lipid (e.g., lipoprotein), glycoprotein or both is employed in an insufficient amount to materially alter the stability characteristics of any of the resulting blood components of the resulting control composition during the stability period. For instance, the amount is an amount at which detectable nuclear morphological characteristics of the nucleated blood component (including any native nuclear cytoplasm granules) exhibit less than a 10%, or even less than a 5%, variation in detected cell counts when analyzed by a digital hematology analyzer as compared with a control having no such lipid (e.g., lipoprotein), glycoprotein or both.

Though the suspension composition may be substantially free of any lipoprotein, it may optionally include lipoprotein. For instance, it may include a lipoprotein in a suitable amount for assuring proper differentiation of white blood cells added to the suspension composition. The suspension composition may include, or it may be free of an antioxidant (e.g., in an amount sufficient to prevent cell lysis during the stability period of a control in which the suspension composition is used).

The suspension composition may include at least one cellular aggregation inhibition ingredient, or may be free of any cellular aggregation inhibition ingredient. The suspension composition may include a surfactant (e.g., in an amount sufficient to effect a surface energy characteristic of any of the simulated blood cells), or it may be free of any surfactant. Examples of surfactants can be found in U.S. Pat. No. 5,250,438, (see, e.g., column 3), incorporated by reference.

In general, as to all embodiments, the aqueous buffered solution of the suspension composition may include at least one buffering agent. For example, it may be zwitterionic buffering agent. The at least one buffering agent may include a sulfonic acid moiety. The buffering agent may be selected from one or any combination of 3-Morpholinopropane-1-sulfonic acid (MOPS); 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid (TES); or 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES). The at least one buffering agent may be present in an amount of up to about 7 percent, up to about 5 percent or up to about 3 percent of the suspension composition. The at least one buffering agent may be present in an amount of greater than about 0.5 percent or greater than about 1 percent of the suspension composition.

The suspension composition may include at least one antimicrobial. The at least one antimicrobial may be part of the aqueous buffered solution or a separate ingredient. The at least one antimicrobial may be organic or inorganic. The at least one antimicrobial may include a biocide, a microbe growth inhibitor, and/or a microbe reproduction inhibitor. The at least one anti-microbial may be a bacteriostatic ingredient (e.g., one that inhibits cytochrome oxidase in gram negative bacteria). The at least one anti-microbial may be an anti-fungal ingredient. The at least one anti-microbial may be an anti-yeast ingredient. Examples of suitable antimicrobials include one or more antimicrobials selected from chloramphenicol, sodium azide, neomycin sulfate, Rifampicin minocycline, ciproflaxin, doxycycline, sulfasalazine or the like. The at least one antimicrobial may be present in an amount of up to about 5%, up to about 3% or up to about 1% percent of the suspension composition.

The suspension composition may have a pH ranging from about 6 to about 8. Suitable amounts of neutralizing agents may be employed in the suspension composition. For example, a relatively mild acid such and/or a relatively mild base such as sodium hydroxide may be titrated into the suspension composition as needed to achieve the desired pH level.

As gleaned from the above, it is envisioned that the suspension composition may include one or more inorganic compounds. The inorganic compound may include a metallic atom or cation, such as an atom or cation of an alkali metal, an alkaline earth metal, a transition metal, or any combination thereof. For example, it is possible that the resulting suspension composition will have one or more metal atoms or cations selected from magnesium (Mg), calcium (Ca), sodium (Na), potassium (K), lithium (Li), iron (Fe), or otherwise. The amount of the metal atoms or cations may be quantified as a proportion relative to the polysaccharide of the suspension composition. For example, the amount of atoms or cations by weight relative to the polysaccharide may range from about 0.1:1 to about 2:1 (e.g., about 0.3:1 to about 1:1).

To the extent not covered in the above, the suspension composition may include one or more other ingredients, including one or any combination of an alcohol, a surfactant; a protease inhibitor; serum albumin protein; an anticoagulant (e.g., ethylenediaminetetraacetic acid “EDTA”), a gelatin, an aldehyde (e.g., glutaraldehyde and/or formaldehyde), a polyol (e.g., polyethylene glycol), a cellulosic agent, an antioxidant, a protein, a blood serum fraction, plasma, amino acid precursor, a cholesterol (e.g., a lipoprotein), or any combination of the above.

In general, water used for the aqueous compositions herein may be distilled water, deionized water, filtered water, any combination thereof or another source of water that is free of detectable amounts of contaminants that would materially impact performance of the suspension composition.

The teachings herein also contemplate a blood control composition (e.g., a white blood cell control composition) adapted for use in a digital imaging hematology analyzer comprising the suspension composition of the teachings, as well as the use of the composition. For instance, the teachings envision a method of using the suspension composition including a step of dispensing the suspension composition onto a substrate, and at least partially evaporating water from the aqueous buffered suspension composition. Thereafter, a digital image can be made. For instance, when cells are deposited onto a substrate with the suspension composition, a digital image may be made of the cells. The image may be analyzed.

Turning now to the accompanying FIGS. 1, 2, 3 a, 3 b, 4 a, 4 b, and 5 various benefits and advantages of the teachings can be further gleaned. Except as otherwise described, the images are believed representative of compositions that would result using a suspension medium, generally, of the present teachings, and particularly the suspension medium described below in Example 1. The images are believed representative of compositions that would result from simulated cell components that include simulated leukocytes, wherein the simulated leukocytes are derived from human blood cells. Similar results are also expected when the simulated leukocytes are derived from non-human blood cells.

FIG. 1 is a micrograph illustrating cells of fresh human whole blood, as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be detectable by a digital imaging hematology analyzer. Examples of the cellular components are labeled for reference purposes. Upon draw, the respective cellular components of the fresh human whole blood substantially identically resemble the cellular components as would be circulating within person from whom the blood was drawn.

FIG. 2 is a micrograph illustrating simulated leukocytes cells in a freshly prepared suspension composition of the present teachings as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be detectable by a digital imaging hematology analyzer. As seen from FIG. 2, there is substantial identify as between the simulated cellular components and the cellular components of FIG. 1. In accordance with the teachings in general, the suspension medium of the present teachings is particularly attractive for us with simulated blood cell components (e.g., at least simulated leukocytes, such as stabilized human leukocytes).

FIGS. 3a and 3b are included for comparison.

FIG. 3a is an enlarged micrograph illustrating respective examples of simulated leukocyte subpopulation cells and other simulated cell components in a suspension composition of the present teachings, the components and suspension composition being freshly prepared, as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be detectable by a digital imaging hematology analyzer.

For comparison with FIG. 3a , FIG. 3b is an enlarged micrograph illustrating respective examples of leukocyte subpopulation cells and other simulated cell components after storage at about 2 to about 10° C. for 105 days in a suspension composition of the present teachings as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be detectable by a digital imaging hematology analyzer. The image illustrates that as between the freshly prepared materials of FIG. 3a and those of FIG. 3b , there are indistinguishable differences if any. As expected in general for the teachings herein, the nucleic subject matter within the granulated cells, in particular, remains intact through a useful life orders of magnitude longer than it would if not suspending in the suspension medium of the teachings (e.g., at least 105 days).

FIGS. 4a and 4b are included for comparison.

FIG. 4a is a micrograph to illustrate an example of simulated leukocyte cells in a suspension medium including a stabilizing agent (e.g., a polysaccharide, such as chitosan or another glucosamine, having a polymerization degree ranging from greater than one to about 100) of the present teachings after about three weeks as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be detectable by a digital imaging hematology analyzer. Consistent with the illustrations of the teachings in FIGS. 2, 3 a and 3 b, the cellular components resemble those of fresh whole blood (e.g., fresh human whole blood), as seen in FIG. 1.

FIG. 4b is a micrograph to illustrate an example of simulated leukocyte cells of the present teachings in a suspension medium as in FIG. 4a , but absent any stabilizing agent of FIG. 4a after about three weeks as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be detectable by a digital imaging hematology analyzer. As can be seen, there is substantial visible degradation. For example, at least the simulated monocytes show considerable transformation from their expected state when suspended in the suspension medium of the present teachings.

FIG. 5 is a micrograph to illustrate an example of a prior art hematology control, absent any stabilizing agent of the present teachings, as viewed by optical microscopy (oil immersion lens at 100×), in a form as would be analyzed by a digital imaging hematology analyzer. It can be seen how nuclear matter is not identifiable.

EXAMPLES

Other benefits and advantages of the teachings will be understood upon review of the following Examples, which provide additional illustrative details of the present teachings.

Example 1

The suspension composition of Table 1 is prepared and predetermined amounts of simulated blood cells is added into it. Water makes up the balance. Concentrations are expressed in weight/volume percentages. To the suspension composition, simulated blood cell components are added according to three different predetermined amounts for each to form a resulting control composition. The three amounts correspond respectively to three different levels—a low abnormal level (“L.1”), a normal healthy level (“L.2”) and a high abnormal level (“L.3). A stability study is performed. The amounts for each leukocyte sub-population reported are provided in numbers (#) and percentage of the overall leukocyte population (%). Measurements are taken at the time the resulting control composition, day 56 of the study and day 105 of the study. The data are collected on a Roche Cobas m511 hematology Analyzer. After preparation of the resulting control composition, and throughout the duration of the study, the resulting control composition is maintained at a temperature of from about 2 to about 10° C. The results show that the suspension medium contributes to stability of the simulated blood cell components of the resulting control composition. This is consistent with the comparative images of FIGS. 3a and 3b .

TABLE 1 Concentration (Pre-cell Ingredient Addition)(w/v %) EDTA, Disodium 1.10% Magnesium Chloride 0.03% HEPES 1.19% Calcium Acetate 0.05% Polyethylene Glycol 20,000 1.00% Urea 0.50% Sodium Chloride 2.64% Chloramphenicol 0.01% Sodium Azide 0.10% Bovine Serum Albumin 1.00% Chitosan Oligosaccharide 0.50% Sodium Hydroxide 0.18%

The composition is analyzed using a Roche Cobas m511™ analyzer, with all levels analyzed in triplicate and reported as the average of the three analyses. Tests are performed on two lots of compositions. Results are reported in the below Tables 2 and 3, respectively for the first lot and the second lot.

Table 2

TABLE 2 L.1 Day# 0 56 105 L.2 Day# 0 56 105 L3 Day# 0 56 105 WBC 15.92 15.67 15.33 WBC 8.00 7.45 7.77 WBC 2.40 2.17 2.25 RBC 2.25 2.33 2.35 RBC 4.04 3.97 4.10 RBC 5.06 5.15 5.36 HGB 5.2 5.1 5.2 HGB 10.8 10.5 10.9 HGB 16.4 16.6 17.1 HCT 15.5 15.5 15.8 HCT 31.7 30.7 31.8 HCT 46.0 46.4 48.3 MCV 69.0 66.6 67.2 MCV 78.3 77.2 77.6 MCV 90.9 90.0 90.1 MCH 22.9 22.1 22.1 MCH 26.8 26.5 26.7 MCH 32.4 32.1 31.9 MCHC 33.1 33.2 32.8 MCHC 34.2 34.3 34.4 MCHC 35.7 35.7 35.4 PLT 432 453 467 PLT 198 221 204 PLT 56 65 61 RDW 15.6 15.9 16.2 RDW 14.0 14.5 14.1 RDW 12.9 12.5 12.5 SD RDW 38.8 38.2 39.3 SD RDW 39.4 40.3 39.5 SD RDW 42.2 40.7 40.5 MPV 9.8 9.9 9.7 MPV 9.5 9.2 9.3 MPV 8.9 9.2 9.3 % nRBC 0.3 0.1 0.1 % nRBC 19.5 18.6 13.6 % nRBC 10.9 10.6 9.9 # nRBC 0.0 0.0 0.0 # nRBC 1.6 1.4 1.1 # nRBC 0.3 0.2 0.2 % RETIC 7.04 7.29 6.78 % RETIC 3.93 3.53 2.60 % RETIC 0.84 0.65 0.21 # RETIC 0.16 0.18 0.16 # RETIC 0.16 0.14 0.11 # RETIC 0.04 0.04 0.01 % NEUT 59.9 59.6 55.4 % NEUT 59.2 58.3 56.4 % NEUT 59.1 59.0 58.6 # NEUT 9.54 9.36 8.50 # NEUT 4.74 4.35 4.38 # NEUT 1.42 1.28 1.32 % LYM 22.6 22.1 24.1 % LYM 22.5 23.3 23.9 % LYM 22.4 20.5 21.6 # LYM 3.60 3.46 3.70 # LYM 1.80 1.74 1.86 # LYM 0.54 0.45 0.49 % MONO 10.1 9.1 10.1 % MONO 12.8 12.8 13.0 % MONO 14.7 16.1 16.2 # MONO 1.60 1.43 1.55 # MONO 1.03 0.96 1.01 # MONO 0.35 0.35 0.36 % EOS 7.1 8.5 9.7 % EOS 5.0 4.7 6.1 % EOS 3.5 3.9 3.2 # EOS 1.12 1.33 1.48 # EOS 0.40 0.35 0.47 # EOS 0.08 0.08 0.07 % BASO 0.4 0.7 0.7 % BASO 0.4 0.8 0.7 % BASO 0.2 0.5 0.5 # BASO 0.06 0.10 0.10 # BASO 0.03 0.06 0.05 # BASO 0.01 0.01 0.01

Table 3

TABLE 3 L.1 Day# 0 52 105 L.2 Day# 0 52 105 L.3 Day# 0 52 105 WBC 18.60 19.29 18.90 WBC 9.20 9.18 9.12 WBC 2.71 2.85 2.67 RBC 2.48 2.52 2.44 RBC 4.29 4.35 4.18 RBC 5.36 5.54 5.42 HGB 5.9 6.1 5.9 HGB 11.7 11.8 11.4 HGB 17.9 18.4 18.0 HCT 17.5 18.0 17.4 HCT 33.5 33.9 33.1 HCT 49.4 50.8 50.1 MCV 70.7 71.3 71.1 MCV 78.1 78.0 79.1 MCV 92.2 91.6 92.4 MCH 23.9 24.2 24.2 MCH 27.2 27.1 27.3 MCH 33.4 33.2 33.4 MCHC 33.8 34.0 34.0 MCHC 34.9 34.8 34.6 MCHC 36.2 36.2 36.1 PLT 576 583 559 PLT 261 272 252 PLT 76 81 80 RDW 14.4 13.8 13.8 RDW 12.4 11.6 11.6 RDW 10.6 9.4 9.9 StDev RDW 36.7 35.2 35.3 StDev RDW 34.8 32.6 33.0 StDev RDW 35.1 30.9 33.0 MPV 8.6 8.5 8.1 MPV 8.7 8.4 8.1 MPV 8.7 8.7 8.3 % nRBC 0.0 0.1 0.0 % nRBC 20.2 19.5 18.8 % nRBC 10.8 10.5 11.1 # nRBC 0.0 0.0 0.0 # nRBC 1.9 1.8 1.7 # nRBC 0.3 0.3 0.3 % RETIC 5.15 4.36 4.06 % RETIC 1.89 2.10 1.84 % RETIC 0.02 0.03 0.00 # RETIC 0.13 0.11 0.10 # RETIC 0.08 0.09 0.08 # RETIC 0.00 0.00 0.00 % NEUT 59.8 59.0 61.3 % NEUT 60.7 59.5 61.9 % NEUT 59.6 59.1 59.4 # NEUT 11.12 11.38 11.58 # NEUT 5.58 5.46 5.65 # NEUT 1.62 1.69 1.58 % LYM 37.3 38.9 35.8 % LYM 36.2 37.1 35.0 % LYM 35.2 35.9 36.6 # LYM 6.94 7.51 6.76 # LYM 3.33 3.41 3.20 # LYM 0.95 1.03 0.95 % MONO 2.2 1.6 2.4 % MONO 2.3 3.0 2.5 % MONO 3.4 3.9 3.6 # MONO 0.41 0.30 0.46 # MONO 0.22 0.28 0.23 # MONO 0.09 0.11 0.09 % EOS 0.6 0.5 0.4 % EOS 0.5 0.2 0.4 % EOS 1.4 1.1 1.4 # EOS 0.11 0.09 0.08 # EOS 0.05 0.02 0.03 # EOS 0.04 0.03 0.04 % BASO 0.1 0.2 0.1 % BASO 0.2 0.2 0.2 % BASO 0.1 0.1 0.0 # BASO 0.02 0.03 0.02 # BASO 0.01 0.02 0.01 # BASO 0.00 0.00 0.00

For the above tables the following abbreviations are used: WBC: white blood cell; RBC: red blood cell; HGB: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular mass; MCHC: mean corpuscular hemoglobin concentration; PLT: platelet; RDW: red blood cell distribution width; SD RDW: standard deviation for red blood cell distribution width; MPV: mean platelet volume; nRBC: nucleated red blood cell; RETIC: reticulocyte; NEUT: neutrophil; LYM: lymphocyte; MONO: monocyte; EOS: eosinophil; BASO: basophil.

General Remarks Applicable to all Teachings

As used herein, unless otherwise stated, the teachings envision that any member of a genus (list) may be excluded from the genus; and/or any member of a Markush grouping may be excluded from the grouping.

Unless otherwise stated, any numerical values recited herein include all values from the lower value to the upper value in increments of one unit provided that there is a separation of at least 2 units between any lower value and any higher value. As an example, if it is stated that the amount of a component, a property, or a value of a process variable such as, for example, temperature, pressure, time and the like is, for example, from 1 to 90, preferably from 20 to 80, more preferably from 30 to 70, it is intended that intermediate range values such as (for example, 15 to 85, 22 to 68, 43 to 51, 30 to 32 etc.) are within the teachings of this specification. Likewise, individual intermediate values are also within the present teachings. For values which are less than one, one unit is considered to be 0.0001, 0.001, 0.01 or 0.1 as appropriate. These are only examples of what is specifically intended and all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application in a similar manner. As can be seen, the comparative teaching of amounts expressed as weight/volume percent for two or more ingredients also encompasses relative weight proportions of the two or more ingredients to each other, even if not expressly stated. For example, if a teaching recites 2% A, and 5% B, then the teaching also encompasses a weight ratio of A:B of 2:5. Unless otherwise stated, all ranges include both endpoints and all numbers between the endpoints. The use of “about” or “approximately” in connection with a range applies to both ends of the range. Thus, “about 20 to 30” is intended to cover “about 20 to about 30”, inclusive of at least the specified endpoints.

The disclosures of all articles and references, including patent applications and publications, are incorporated by reference for all purposes.

The term “consisting essentially of to describe a combination shall include the elements, ingredients, components or steps identified, and such other elements ingredients, components or steps that do not materially affect the basic and novel characteristics of the combination. The use of the terms “comprising” or “including” to describe combinations of elements, ingredients, components or steps herein also contemplates embodiments that consist essentially of (namely, the presence of any additional elements, ingredients, components or steps, does not materially affect the properties and/or benefits derived from the teachings; or even consist of the elements, ingredients, components or steps.

Plural elements, ingredients, components or steps can be provided by a single integrated element, ingredient, component or step. Alternatively, a single integrated element, ingredient, component or step might be divided into separate plural elements, ingredients, components or steps. The disclosure of “a” or “one” to describe an element, ingredient, component or step is not intended to foreclose additional elements, ingredients, components or steps. All references herein to elements or metals belonging to a certain Group refer to the Periodic Table of the Elements published and copyrighted by CRC Press, Inc., 1989. Any reference to the Group or Groups shall be to the Group or Groups as reflected in this Periodic Table of the Elements using the IUPAC system for numbering groups.

It is understood that the above description is intended to be illustrative and not restrictive. Many embodiments as well as many applications besides the examples provided will be apparent to those of skill in the art upon reading the above description. The scope of the teachings should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. The disclosures of all articles and references, including patent applications and publications, are incorporated by reference for all purposes. The omission in the following claims of any aspect of subject matter that is disclosed herein is not a disclaimer of such subject matter, nor should it be regarded that the inventors did not consider such subject matter to be part of the disclosed inventive subject matter.

The explanations and illustrations presented herein are intended to acquaint others skilled in the art with the teachings, its principles, and its practical application. Those skilled in the art may adapt and apply the teachings in its numerous forms, as may be best suited to the requirements of a particular use. Accordingly, the specific embodiments of the present teachings as set forth are not intended as being exhaustive or limiting of the teachings. The scope of the teachings should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. The disclosures of all articles and references, including patent applications and publications, are incorporated by reference for all purposes. Other combinations are also possible as will be gleaned from the following claims, which are also hereby incorporated by reference into this written description. 

1) A suspension composition adapted for use in assuring quality control of a digital imaging hematology analyzer, comprising: a suspension medium (optionally including a buffered aqueous solution) with which at least one simulated nucleated blood component is mixed in a predetermined amount, the suspension medium including at least one stabilizing agent in an amount capable of preserving relevant detectable size and morphology, including detectable nuclear morphological characteristics of the nucleated blood component (including any native nuclear cytoplasm granules), when stored at about 2 to about 10° C. for a period of at least 3 days from when the at least one simulated nucleated blood component is initially mixed with the suspension medium. 2) A suspension composition for simulated white blood cells of a hematology analyzer control formulation and retaining detectable morphological characteristics of the simulated blood cells, comprising: a. a buffered aqueous solution; and b. at least one stabilizing agent that includes at least one polysaccharide having a polymerization degree ranging from greater than one to about 100, the at least one stabilizing agent being present in an amount sufficient for preserving stability of the relevant detectable characteristics of the simulated blood cells for a period of at least 3 days, after being stored during such period at about 2 to about 10° C., upon suspending the simulated blood cells; wherein upon mixing the suspension composition with the simulated blood cells, the resulting mixture is capable of dispensing through a nozzle for delivery to a substrate for analysis by a digital imaging hematology analyzer. 3) The suspension composition of claim 1 or 2, wherein the suspension composition is adapted for use in digital imaging hematology instrument that creates and analyzes an image by a computer implemented technique of a sample that has been dispensed onto a substrate. 4) The suspension composition of any of the above claims, wherein the suspension composition is adapted, upon mixing with the simulated blood cells, for dispensing through a nozzle for delivery by printing to a transparent substrate and subsequent analysis by a digital imaging hematology analyzer, without any material damage (e.g., damage to excess of five percent (5%) by number of total simulated blood cells) to the blood cells. 5) The suspension composition of any of the above claims, wherein the at least one stabilizing agent is present in an amount sufficient for preserving stability of the detectable morphological characteristics of the simulated blood cells for a period of at least 30 days, after being stored during such period at about 2 to about 10° C., upon suspending the blood cells; wherein the simulated blood cells include nucleated blood cells, and wherein the detectable morphological characteristics that are preserved include size, a nucleus morphology and morphology of other native nuclear cytoplasm granules. 6) The suspension composition of any of the above claims, wherein the aqueous buffered solution includes at least one buffering agent, and at least one antimicrobial. 7) The suspension composition of any of the above claims, wherein the aqueous buffered solution includes at least one dispersion agent for reducing aggregation of the simulated blood cells as compared with the aqueous buffered solution without the dispersion agent. 8) The suspension composition of any of the above claims, wherein the suspension composition has a pH ranging from about 6 to about
 8. 9) The suspension composition of any of the above claims, wherein the at least one stabilizing agent includes least one amino polysaccharide having a polymerization degree ranging from greater than one to about
 100. 10) The suspension composition of any of the above claims, wherein the at least one stabilizing agent includes least one polysaccharide having a polymerization degree ranging from greater than about 5 to about
 40. 11) The suspension composition of any of the above claims wherein the at least one stabilizing agent is an oligosaccharide having a weight average molecular weight (measured by high performance liquid chromatography and gel permeation chromatography (HPLC/GPC)) from about 500 to about 5000 (e.g., about 1000 to about 3000). 12) The suspension composition of any of the above claims wherein the at least one stabilizing agent is a glucosamine oligosaccharide having a weight average molecular weight (measured by high performance liquid chromatography and gel permeation chromatography (HPLC/GPC)) from about 1000 to about
 3000. 13) The suspension composition of any of the above claims, wherein the at least one stabilizing agent includes a glucosamine. 14) The suspension composition of any of the above claims, wherein the at least one stabilizing agent includes one or any combination of chitin, a derivative of chitin, a chitosan, a salt of a chitosan or a derivative of a chitosan. 15) The suspension composition of any of the above claims wherein the at least one stabilizing agent is selected from D-(+)-glucosamine, N-acetyl-D-glucosamine, chitosan acetate, chitosan lactate, chitosan oligosaccharide, carboxyl methyl chitosan, or any combination thereof. 16) The suspension composition of any of the above claims, wherein the at least one stabilizing agent is present in an amount up to about ten percent (10%) of the suspension composition. 17) The suspension composition of any of the above claims, wherein the simulated blood cells include simulated nucleated leukocytes, nucleated red blood cells or both. 18) The suspension composition of any of the above claims, wherein the at least one stabilizing agent is present in an amount up to about ten percent (10%) of a resulting control composition admixture including the suspension composition and the simulated blood cells. 19) The suspension composition of any of the above claims, wherein the suspension composition and any resulting control composition employing the suspension composition is substantially free of any added lipoprotein. 20) A white blood cell control composition adapted for use in a digital imaging hematology analyzer comprising the suspension composition of any of the above claims. 21) A method of using the suspension composition of any of the above claims, comprising a step of dispensing the suspension composition onto a substrate, and at least partially evaporating water from the aqueous buffered suspension composition. 